Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis
Sadaphal P, Astemborski J, Graham N, Sheely L, Bonds M, Madison A, Vlahov D, Thomas D, Sterling T. Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis. Clinical Infectious Diseases 2001, 33: 1687-1691. PMID: 11641824, PMCID: PMC2650436, DOI: 10.1086/323896.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersTuberculosis infectionValue elevationDrug usersCurrent injection drug useLatent Mycobacterium tuberculosis infectionHepatitis C virus infectionHepatitis B surface antigenLow HCV prevalenceC virus infectionIsoniazid preventive therapyInjection drug useM. tuberculosis infectionMycobacterium tuberculosis infectionHIV-1 infectionHuman immunodeficiency virusB surface antigenConcurrent alcohol useDrug discontinuationHCV prevalencePreventive therapyImmunodeficiency virusProspective studyTransaminase values